|Abatacept||Abciximab||Abecarnil||Abetimus Sodium||Abietic Acid|
|Systematic (IUPAC) name|
|acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide|
|Pregnancy cat.||X (US)|
|Mol. mass||1416.06 g/mol|
|(what is this?)|
Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.
It was originally marketed by Praecis Pharmaceuticals as Plenaxis, and is now marketed by Speciality European Pharma in Germany after receiving a marketing authorisation in 2005.